BAM
RPRX icon

Bellevue Asset Management’s Royalty Pharma RPRX Stock Holding History

Bellevue Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50
Closed -$1.54K – 475
2023
Q2 		$1.54K Hold
50
– – ﹤0.01% 436
2023
Q1 		$1.8K Hold
50
– – ﹤0.01% 422
2022
Q4 		$1.96K Buy
+50
New +$2.09K ﹤0.01% 403

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Asset Management's RPRX Position: Q3 2023 in Review

Bellevue Asset Management sold out of Royalty Pharma (RPRX) in Q3 2023, closing a stake of 50 shares — an estimated $1.54K sold.

Bellevue Asset Management first reported a position in RPRX in Q4 2022 and held it in 3 quarters. The position peaked at $1.96K in Q4 2022. 313 funds tracked by Wall St. Rank hold RPRX as of Q3 2023.

  • Bellevue Asset Management reported no remaining Royalty Pharma position as of Q3 2023 after selling out during the quarter.
  • Bellevue Asset Management sold 50 Royalty Pharma shares in Q3 2023, an estimated $1.54K.
  • Bellevue Asset Management first reported a position in Royalty Pharma in Q4 2022 and held it in 3 quarters.
  • Bellevue Asset Management's Royalty Pharma position peaked at $1.96K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2023.

Based on Bellevue Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.